These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10022531)

  • 61. Investigation of hFVIII production in mammary glands of transgenic mice.
    Mohammadian T; Rassi H
    Monoclon Antib Immunodiagn Immunother; 2014 Oct; 33(5):325-9. PubMed ID: 25358000
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Genetic therapy for hemophiliacs--therapeutic potential and technological limits].
    Michou AI; Christ M; Pavirani A; Mehtali M
    Transfus Clin Biol; 1997; 4(3):251-61. PubMed ID: 9264782
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bone-directed expression of Col1a1 promoter-driven self-inactivating retroviral vector in bone marrow cells and transgenic mice.
    Stover ML; Wang CK; McKinstry MB; Kalajzic I; Gronowicz G; Clark SH; Rowe DW; Lichtler AC
    Mol Ther; 2001 Apr; 3(4):543-50. PubMed ID: 11319916
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells.
    Marx JC; Allay JA; Persons DA; Nooner SA; Hargrove PW; Kelly PF; Vanin EF; Horwitz EM
    Hum Gene Ther; 1999 May; 10(7):1163-73. PubMed ID: 10340548
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sustained expression of Epstein-Barr virus episomal vector mediated factor VIII in vivo following muscle electroporation.
    Mei WH; Qian GX; Zhang XQ; Zhang P; Lu J
    Haemophilia; 2006 May; 12(3):271-9. PubMed ID: 16643213
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic approaches for treating hemophilia A using embryonic stem cells.
    Kasuda S; Tatsumi K; Sakurai Y; Shima M; Hatake K
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):64-70. PubMed ID: 27131224
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models.
    Arruda VR
    J Thromb Haemost; 2006 Jun; 4(6):1215-7. PubMed ID: 16706962
    [No Abstract]   [Full Text] [Related]  

  • 68. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.
    Miao CH; Ye P; Thompson AR; Rawlings DJ; Ochs HD
    Blood; 2006 Jul; 108(1):19-27. PubMed ID: 16507778
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transplantation of murine bone marrow stromal cells under the kidney capsule to secrete coagulation factor VIII.
    Oh T; Peister A; Ohashi K; Park F
    Cell Transplant; 2006; 15(7):637-45. PubMed ID: 17176615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
    Greig JA; Smith MK; Nordin JML; Goode T; Chroscinski EA; Buza EL; Schmidt N; Kattenhorn LM; Wadsworth S; Wilson JM
    Hum Gene Ther; 2022 Apr; 33(7-8):421-431. PubMed ID: 34652966
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver.
    Park F; Ohashi K; Kay MA
    Blood; 2000 Aug; 96(3):1173-6. PubMed ID: 10910939
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.
    Sabatino DE; Freguia CF; Toso R; Santos A; Merricks EP; Kazazian HH; Nichols TC; Camire RM; Arruda VR
    Blood; 2009 Nov; 114(20):4562-5. PubMed ID: 19770361
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A.
    Lin Y; Chang L; Solovey A; Healey JF; Lollar P; Hebbel RP
    Blood; 2002 Jan; 99(2):457-62. PubMed ID: 11781225
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.
    Mertens K; Donath MJ; van Leen RW; de Keyzer-Nellen MJ; Verbeet MP; Klaasse Bos JM; Leyte A; van Mourik JA
    Br J Haematol; 1993 Sep; 85(1):133-42. PubMed ID: 8251380
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Induction of tolerance to human factor VIII in mice.
    Chao H; Walsh CE
    Blood; 2001 May; 97(10):3311-2. PubMed ID: 11342466
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.
    Chen L; Zhu F; Li J; Lu H; Jiang H; Sarkar R; Arruda VR; Wang J; Zhao J; Pierce GF; Ding Q; Wang X; Wang H; Pipe SW; Liu XQ; Xiao X; Camire RM; Xiao W
    Mol Ther; 2007 Oct; 15(10):1856-62. PubMed ID: 17653101
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genetic therapy using bone marrow transplantation.
    Giles RE; Hanania EG; Fu S; Deisseroth A
    Cancer Treat Res; 1995; 76():271-80. PubMed ID: 7577339
    [No Abstract]   [Full Text] [Related]  

  • 78. Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells.
    Su RJ; Epp A; Feng J; Roy J; Latchman Y; Wu X; Bolgiano D; Josephson NC
    Mol Ther; 2011 Oct; 19(10):1896-904. PubMed ID: 21772255
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The establishment of murine blood outgrowth endothelial cells and observations relevant to gene therapy.
    Somani A; Nguyen J; Milbauer LC; Solovey A; Sajja S; Hebbel RP
    Transl Res; 2007 Jul; 150(1):30-9. PubMed ID: 17585861
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gene therapy for hemophilia A. Friend or foe?
    Lippi G; Franchini M; Saenko EL
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):395-9. PubMed ID: 19542881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.